More on Safety of Stopping MAC Prophylaxis
Results from a retrospective report of patients discontinuing secondary MAC prophylaxis lend support to recently updated guidelines suggesting that cessation of antimycobacterial therapy appears safe in antiretroviral-treated patients with a sustained increase in CD4-cell count to >100.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)